2023 World Conference on Lung Cancer (Posters)-EP09.03. Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies

EP09.03. Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies - PDF(Abstract)

Back to course

Pdf Summary

This study examined the outcomes of using extracranial stereotactic body radiation therapy (SBRT) in patients with Stage IV non-small cell lung cancer (NSCLC) who developed induced oligopersistant disease (OpersisD) or oligoprogressive disease (OprogD) while receiving novel targeted agents or immunotherapies. The researchers identified 49 patients who underwent SBRT for OpersisD or OprogD and evaluated outcomes including local control, time to progression, and treatment-related toxicity.<br /><br />The majority of patients (55.1%) were receiving Osimertinib, while 44.89% were on immunotherapy agents such as Pembrolizumab and Nivolumab. SBRT dose fractionation schemas varied, and a total of 77 lesions were treated in various sites including the lung, adrenal glands, lymph nodes, bone, liver, and mediastinum.<br /><br />At a median follow-up of 26.6 months from the first SBRT, local control was achieved in 92.2% of treated lesions. Radiographic progression occurred in 65.3% of patients, and salvage SBRT was performed in 10 cases. Systemic treatment was changed for 51% of patients at a median time of 11.76 months due to disease progression.<br /><br />Notably, 34.7% of patients did not experience progression after SBRT, and 48.9% did not require a change in systemic treatment at the last follow-up. Patients with OpersisD had longer times to radiographic progression and systemic treatment change compared to those with OprogD. No grade 3-5 toxicities were reported with SBRT treatment.<br /><br />Overall, the results suggest that SBRT for Opersis or OprogD in Stage IV NSCLC patients receiving novel targeted agents or immunotherapies is safe and may prolong the time until a change in systemic therapy is needed. However, further prospective studies are needed to validate these findings.

Asset Subtitle

Philip Blumenfeld

Meta Tag

Speaker Philip Blumenfeld

Topic Metastatic NSCLC: Local Therapies - OIigometastatic NSCLC

Keywords

extracranial stereotactic body radiation therapy

SBRT

Stage IV non-small cell lung cancer

NSCLC

induced oligopersistant disease

OpersisD

oligoprogressive disease

OprogD

novel targeted agents

immunotherapies